Yueyang Xingchang and Hebei Huaan biopharmaceuticals are bound to be tricky.

What you said is reasonable, but in the absence of conclusive evidence, everything is just speculation, and no one knows what will happen. Yueyang Xingchang, as the major shareholder of Chongqing Kangwei products, should take good care of Helicobacter pylori vaccine and realize industrialization as soon as possible. Now the clinical trial of the vaccine has been completed, and the industrial pilot scale-up stage has not been completed, which is really hard to get. The interest disputes involved are complicated. Hebei Huaan Bio has no experience in producing and selling vaccines. How to choose him as a strategic investor must be tricky. The minority shareholder Yangchun Bio explained this point in this lawsuit. Next, let's take a look at the court ruling on August 17, hoping to straighten out the interests of all parties as soon as possible.